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Methylenetetrahydrofolate reductase (MTHFR) is a critical folate-metabolising enzyme
which requires riboﬂavin as its co-factor. A common polymorphism (677CT) in the
MTHFR gene results in reduced MTHFR activity in vivo which in turn leads to impaired
folate metabolism and elevated homocysteine concentrations. Homozygosity for this poly-
morphism (TT genotype) is associated with an increased risk of a number of conditions
including heart disease and stroke, but there is considerable variability in the extent of excess
risk in various reports. The present review will explore the evidence which supports a role for
this polymorphism as a risk factor for a number of adverse health outcomes, and the poten-
tial modulating roles for B-vitamins in alleviating disease risk. The evidence is convincing in
the case which links this polymorphism with hypertension and hypertensive disorders of
pregnancy, particularly preeclampsia. Furthermore, elevated blood pressure was found to
be highly responsive to riboﬂavin intervention speciﬁcally in individuals with the MTHFR
677TT genotype. Future intervention studies targeted at these genetically predisposed indi-
viduals are required to further investigate this novel gene–nutrient interaction. This poly-
morphism has also been associated with an increased risk of neural tube defects (NTD)
and other adverse pregnancy outcomes; however, the evidence in this area has been incon-
sistent. Preliminary evidence has suggested that there may be a much greater need for
women with the MTHFR 677TT genotype to adhere to the speciﬁc recommendation of
commencing folic acid prior to conception for the prevention of NTD, but this requires
further investigation.
MTHFR 677CT polymorphism: Folate: Riboﬂavin: CVD: Neural tube defects:
Hypertension
The common 677CT variant in the gene that encodes
the enzyme methylenetetrahydrofolate reductase
(MTHFR) is widely recognised as the most important
genetic determinant of elevated homocysteine concen-
tration in healthy populations. Emerging evidence links
the MTHFR 677CT polymorphism with a greater
risk of CHD(1), stroke(2) and more recently hyperten-
sion(3), although there is considerable variability in the
extent of excess disease risk in different populations, an
observation that is generally explained by differences in
folate status. The potential roles of folate and the related
B-vitamins in the risk of these and other common dis-
eases have been widely investigated over the past two
decades, but relatively few studies have speciﬁcally inves-
tigated the roles of the relevant gene–nutrient inter-
actions in modulating the risk of disease.
The role of maternal folate status in early pregnancy
for the prevention of neural tube defects (NTD) is well
established(4,5). In addition, other pregnancy compli-
cations such as gestational hypertension and preeclamp-
sia have been associated with low maternal folate
status(6,7). Although the mechanisms linking low folate
status to these pregnancy complications are not fully
understood, the identiﬁcation of genes that may predis-
pose women to adverse pregnancy events has been the
focus of much research. There is now strong evidence
to support a role for the MTHFR 677CT polymorph-
ism in adverse pregnancy outcomes(8,9). The present
paper will explore the evidence linking this polymorph-
ism with various disease states and the potential modu-
lating role for B-vitamins in alleviating any excess
disease risk.
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MTHFR 677TT genotype in C1 metabolism
The MTHFR enzyme requires the B-vitamin riboﬂavin
in its co-enzymatic form ﬂavin adenine dinucleotide to
catalyse the conversion of 5,10-methylenetetrahydrofolate
to 5-methyltetrahydrofolate. This enzyme plays a key
role in regulating the availability of methyl groups
required for the remethylation of homocysteine into
methionine. The common 677CT variant results in a
less active thermolabile MTHFR enzyme typically lead-
ing to elevated homocysteine concentration in vivo(10).
In vitro evidence indicates that the reduced activity of
the variant enzyme is the result of an increased propen-
sity to dissociate from its FAD co-factor(11,12). The
ﬁnding of lower erythrocyte folate concentrations in
individuals with the homozygous mutant TT genotype
compared with those without this genetic variant, has
led to the suggestion that folate requirements may be
increased in these individuals(13). Furthermore, homo-
cysteine concentrations are found to be highest under
conditions of suboptimal folate status in combination
with the TT genotype(14,15).
The B-vitamins folate and riboﬂavin (along with the
metabolically related B-vitamins, B12 and B6) are impor-
tant nutritional determinants of homocysteine concen-
trations. Supplementation with folic acid, the synthetic
form of folate, has been shown to lower elevated homo-
cysteine concentrations by approximately 25% in the
population generally(16). In the case of riboﬂavin, how-
ever, the homocysteine-lowering effects are conﬁned to
those with theMTHFR 677TT genotype. Riboﬂavin sup-
plementation speciﬁcally in individuals with the TT
genotype has been shown to signiﬁcantly lower plasma
homocysteine by 22%, and by as much as 40% in those
with the lowest riboﬂavin status at baseline(17). This
response was not observed in individuals with CC or
CT genotypes (even when baseline riboﬂavin status was
suboptimal) despite a signiﬁcant improvement in riboﬂa-
vin status post-intervention in both genotype groups.
Such evidence conﬁrmed the independent modulating
role of riboﬂavin in determining homocysteine concen-
trations speciﬁcally in individuals with the TT genotype
as ﬁrst suggested by earlier observational studies(18,19).
Association between the MTHFR 677CT
polymorphism and CVD risk
The MTHFR 677CT polymorphism previously
received much attention as the main genetic determinant
of homocysteine(10) and is also independently associated
with an increased risk of CVD and particularly
stroke(1,2,20,21). Several meta-analyses to date have
demonstrated an increased risk of CVD in individuals
with the TT genotype compared to those without this
genetic variant(1,2,20–22) (Table 1). Those studies which
assessed the risk of CHD events estimated a 14–16%
higher risk in individuals with the TT genotype com-
pared to those with the CC genotype(20,23). The most
recent meta-analysis considered published and unpub-
lished results in the area and estimated that the
MTHFR 677TT genotype carried a 15% excess risk of
heart disease (based on published results)(24).







Klerk et al.(1) 23920 All 1·16 (1·05, 1·28)
Europe 1·14 (1·01, 1·28)
North America 0·87 (0·73, 1·05)
Wald et al.(21) 16849 All 1·42 (1·11, 1·84)
Casas et al.(22) 13928 All 1·26 (1·14, 1·40)
North America/Europe 1·21 (1·02, 1·43)
Lewis et al.(20) 57183 All 1·14 (1·05, 1·24)
Middle East 2·61 (1·81, 3·75)
Asia 1·23 (0·94, 1·62)
Europe 1·08 (0·99, 1·18)
North America 0·93 (0·80, 1·10)
Australia 1·04 (0·73, 1·49)
Holmes et al.(2) 45549 All 1·37 (1·25, 1·50)




Clarke et al.(24) 70474 All 1·15 (1·09, 1·21)
Asia 1·49 (1·29, 1·73)
Europe 1·11 (0·93, 1·22)*
USA and Australasia 1·04 (0·79, 1·36)*
* Reported after national folate supplementation in the USA, Canada, Australia, New Zealand and some
but not all European countries.





















Differences in B-vitamin status may in some way
explain the large geographical variation in the extent of
the excess risk, which has previously been reported in
relation to this polymorphism (Table 1). Klerk et al.(1)
and Lewis et al.(20) found no strong evidence to support
an association between the TT genotype and risk of
CHD among North American populations; however,
the polymorphism was linked to an increased risk of
CHD among Asian and Middle Eastern populations. It
was concluded that such geographical differences
reﬂected the inﬂuence of environmental factors (primar-
ily folate status) on the interaction between the poly-
morphism and CVD risk(2,25). In terms of stroke, the
TT genotype was associated with an increased risk in
regions of low folate only; whereas in populations of
optimal folate status or in regions of mandatory folic
acid fortiﬁcation, the effect of the TT genotype on stroke
risk was null(2). Somewhat surprisingly however, recent
prospective evidence from the National Health and
Nutrition Examination Survey cohort reported that the
MTHFR 677TT genotype was associated with a lower
rate of CVD mortality (OR 0·69 (95% CI 0·50, 0. 95)),
although stratiﬁed analysis found that this association
only occurred after the introduction of mandatory folic
acid fortiﬁcation(26).
Overall, the evidence supports a modulating role of
folate on CVD risk in this genetically at-risk group.
However caution is required when interpreting the results
from some observational studies. Further large-scale gen-
etic studies, particularly among populations with sub-
optimal folate status, are required to fully investigate
the extent of CVD risk associated with this polymorph-
ism and to consider the role of metabolically related
B-vitamins linked with folate.
MTHFR 677CT polymorphism and blood pressure
Hypertension, deﬁned as a blood pressure (BP) of
140/90mmHg or greater, is a major risk factor for
CVD, with uncontrolled hypertension associated with
an almost threefold greater risk of developing CVD(27).
Furthermore, elevated BP is recognised as an even stron-
ger predictor of stroke. A modest lowering of systolic BP
by 2-mmHg is estimated to decrease cardiovascular risk
by 10%, whereas a lowering of 10-mmHg is associated
with a 40% reduction in stroke mortality(28).
Approximately 30–60% of BP variability is considered
to be inherited(29,30) and several studies have focused on
investigating genetic variants associated with elevated
BP. Recent genome-wide association studies have inves-
tigated associations between single-nucleotide poly-
morphisms and elevated BP(3,31). One such study,
which included data from 34433 individuals, reported
that the MTHFR loci was one of eight loci related to
BP; however, the authors noted that there may be
other genetic variants linked to the BP located in this
region which have not been considered or are still
unknown(3). Several subsequent investigations of a gen-
ome-wide association studies nature have conﬁrmed the
association between the MTHFR gene and BP
variability(32–34).
The evidence from case–control studies suggests that
there is a graded association between the MTHFR
677T allele and BP risk among hypertensive populations
across different ethnic groups. An early case–control
study in a Caucasian–Australian population reported a
signiﬁcantly higher frequency of the TT genotype in
cases with hypertension compared to controls (after
adjustment for BMI)(35). Within an Asian–Indian popu-
lation, a nearly fourfold increased risk of hypertension
in individuals with the TT genotype was reported(36).
Interestingly, in a large population-based study of over
3000 Japanese people, the TT genotype was associated
with a 42% increased risk of hypertension in women;
however no signiﬁcant association was shown in
men(37). As the evidence accumulated to support an
association between the MTHFR 677CT polymorph-
ism and hypertension risk, a number of meta-analyses
were carried out. One meta-analysis of thirteen case–
control studies(38) conﬁrmed a signiﬁcant association
between the TT genotype and hypertension among the
Asian and the Caucasian populations, albeit signiﬁcant
heterogeneity was reported (OR 1·24 (95% CI 1·02,
1·50)). The most recent meta-analysis, which attempted
to address the issue of heterogeneity by focusing speciﬁ-
cally on Chinese population studies only, reported a
87% increased risk of hypertension in individuals with
the TT genotype compared to those with the CC geno-
type(8). Similarly, case–control studies carried out in
hypertensive patients with various co-morbidities such
as diabetes(39), coronary artery disease(40) and chronic
renal failure(41) have also reported signiﬁcant associ-
ations between this polymorphism and hypertension.
In addition to lifestyle and dietary modiﬁcations,
improvements in the management of BP are largely con-
sidered to be due to the development of effective antihy-
pertensive medications. Such medications are broadly
categorised into ﬁve main classes (diuretics, β-blockers,
calcium channel blockers, angiotension converting
enzyme inhibitors and angiotension II receptor blockers),
all of which have slightly different mechanisms of action.
Only a limited number of studies, however, have investi-
gated whether the BP-lowering effect of antihypertensive
medications is inﬂuenced by theMTHFR 677CT poly-
morphism. Jiang et al.(42) reported an increased diastolic
BP response to treatment with an angiotension convert-
ing enzyme inhibitor in hypertensive patients with the
TT genotype compared to those without the polymorph-
ism. More recently, in a larger cohort of hypertensive
patients with the TT genotype (who expressed the pheno-
type of elevated BP at baseline), an increased diastolic
BP response to treatment with an angiotension convert-
ing enzyme inhibitor was again reported (P=0·038)(43).
Similarly, short-term treatment with a calcium channel
blocker resulted in a signiﬁcantly higher pulse wave
velocity response in patients with the TT genotype com-
pared with those with CC and CT genotypes (P=0·018);
the polymorphism however did not affect the antihyper-
tensive effects of the calcium channel blocker treat-
ment(44). In contrast, other studies (reviewed later)





















suggest that the response to antihypertensive medication
is generally suboptimal in individuals with the TT geno-
type compared to those with the CC or CT genotype.
Given the limited evidence to date, further work is
needed to explore potential interactions between the
MTHFR 677CT polymorphism and the antihyperten-
sive effects of various BP medications.
MTHFR genotype and the modulating potential of
B-vitamins in blood pressure control
Although strong evidence shows an association between
the MTHFR 677CT polymorphism and hypertension,
the interrelationships between MTHFR genotypes,
B-vitamin status and hypertension risk are not generally
appreciated. In one small placebo-controlled, cross-over
design study (n 41), Williams et al.(45) reported a
decreased pulse pressure and arterial stiffness following
short-term folic acid supplementation (5mg/d); an effect
that was reported to be independent of homocysteine
concentration or MTHFR genotype, but the lack of stat-
istical power (i.e. only ﬁve subjects with the TT genotype
were available for investigation) makes such conclusions
questionable. A subsequent intervention study reported
no BP response to short-term folic acid supplementation,
but did observe an association betweenMTHFR T allele
frequency and hypertension risk(46). Owing to the oppor-
tunistic nature of such studies (and therefore the lack of
genotype-driven recruitment) such inconsistent results
are not surprising. Similarly, in the large-scale trials of
CVD risk involving folic acid intervention with or with-
out other B-vitamins, no response of BP has been
reported to date; however, no trial has analysed the
results of BP (or other CVD outcomes) by MTHFR
genotype(47,48).
Given the emerging evidence linking hypertension
with this polymorphism(3) and the established genotype-
speciﬁc response of homocysteine to riboﬂavin sup-
plementation(17), recent research from our Centre has
focused on investigating the BP-lowering potential of
riboﬂavin in hypertensive individuals with the TT geno-
type. In a placebo-controlled trial, premature CVD
patients (pre-screened for the MTHFR 677CT poly-
morphism) were randomised within all three genotype
groups to receive either riboﬂavin (1·6mg/d) or placebo
over a 16-week intervention period. Baseline BP was sig-
niﬁcantly higher in patients with the TT genotype com-
pared to those with other genotypes; an effect that was
most pronounced in those with the lowest baseline
riboﬂavin status (as determined by the biomarker eryth-
rocyte glutathione reductase activation co-efﬁcient).
Systolic and diastolic BP decreased signiﬁcantly (by 13
and 8mmHg, respectively) in those individuals with the
TT genotype but no response was observed in the other
genotype groups(49). A follow-up, cross-over, randomised
controlled trial reinvestigated the effect of riboﬂavin on
BP in the same cohort of high-risk CVD patients 4 years
after the original investigation(50). Although there were
marked changes in prescribed antihypertensive therapy
over the 4-year period, the mean BP of those with the
TT genotype (who originally received riboﬂavin sup-
plementation for the 16-week period) had returned to
pre-intervention levels. When the original treatment
groups were reversed, the genotype-speciﬁc BP-lowering
effect of riboﬂavin was again conﬁrmed(50) with
reductions of 9·2 (SD 12·8) mmHg (P=0·001) and 6·0
(SD 9·9) mmHg (P=0·003) in systolic and diastolic BP,
respectively. Most recently, the responsiveness of BP to
riboﬂavin supplementation in a separate cohort of treated
hypertensive individuals (without overt CVD) with the
TT genotype (n 91) was investigated(51). At baseline,
60% of the participants had failed to achieve target BP
levels (≤140/90mmHg), despite taking three or more
antihypertensive medications. Following riboﬂavin inter-
vention (1·6mg/d for 16 weeks), systolic BP decreased
signiﬁcantly, a ﬁnding which conﬁrmed that the
BP-lowering effects of riboﬂavin in individuals with the
MTHFR 677TT genotype were not conﬁned to high-risk
CVD patients but also applied to hypertensive individ-
uals generally(51).
Although accumulating evidence highlights the
BP-lowering effects of riboﬂavin in hypertensive indi-
viduals with the MTHFR 677CT polymorphism,
the mechanism to explain the role of this gene–nutrient
interaction in BP remains unclear. It is possible how-
ever that the potent vasodilator nitric oxide may be
involved. Decreased vascular concentrations of 5-meth-
lytetrahydrolfolate, a nitric oxide regulator, have been
reported in those with the MTHFR 677TT genotype(52).
By stabilising the variant enzyme via riboﬂavin sup-
plementation, it is possible that normal concentrations
of 5-methyltetrahydrofolate would be restored in vascu-
lar cells, thus improving the bioavailability of nitric
oxide and resulting in BP-lowering speciﬁcally in
those with the TT genotype. Further investigations
are required to explore this and other potential mechan-
isms as well as the role of other B-vitamins involved in
C1 metabolism. Given the known metabolic interdepen-
dencies between the relevant B-vitamins, work is under-
way at this Centre to investigate the independent and
combined effects of riboﬂavin and folic acid on BP in
hypertensive individuals with the TT genotype in a fac-
torial study design. In addition, although convincing
evidence has demonstrated the BP-lowering effects of
low-dose riboﬂavin over a relatively short period of
time (1·6mg/16 weeks)(49–51), it remains to be seen
how variations in dose and duration would inﬂuence
the BP-lowering effects of riboﬂavin in these genetically
at-risk patients.
MTHFR genotype, B-vitamins and pregnancy outcomes
Well-established evidence has accumulated to suggest a
link between the MTHFR 677CT polymorphism and
the risk of certain adverse pregnancy outcomes including
NTD as well as hypertensive disorders such as pree-
clampsia and gestational hypertension; some of which
will be the focus of the next section of this review.





















The link between the B-vitamins and neural tube defects
NTD are of multi-factorial origin and involve both gen-
etic and environmental factors. Landmark studies in the
early 1990s conﬁrmed the protective effects of pericon-
ceptional folic acid supplementation against the ﬁrst
occurrence(4) and reoccurrence(5) of NTD. Of note,
Daly et al.(53) illustrated a dose–response inverse relation-
ship between maternal red cell folate (RCF) and NTD
risk and identiﬁed maternal RCF concentrations of
≥906nmol/l as the level associated with the lowest risk
of an NTD affected pregnancy. Subsequently, folic acid
supplementation levels of 400, 200 or 100μg/d were
reported to produce RCF concentrations, which pre-
dicted reductions in NTD by 47, 41 and 22%,
respectively(54).
Present recommendations, in place in most countries
worldwide, are that women planning a pregnancy should
take a folic acid supplement of 400μg/d for at least
1 month before conception and during the ﬁrst trimester
of pregnancy(55). Reports have conﬁrmed, however, that
the uptake of this recommendation among women of
child bearing age is typically poor(56,57) and so it is not
surprising that the NTD rates have changed very little
across several European countries as a result of these
folic acid recommendations(58). In contrast, the introduc-
tion of mandatory fortiﬁcation of food with folic acid in
the USA has successfully increased both serum and RCF
concentrations among women of childbearing age(59)
which has coincided with a 27–50% reduction in the
reported prevalence of NTD in the USA and
Canada(60,61). At a global level, folic acid fortiﬁcation
of food in countries worldwide has led to an estimated
46% reduction in the prevalence of NTD since 2008(62).
The role of the MTHFR 677CT polymorphism
in neural tube defects
To date, no single gene or genetic variant has been
identiﬁed as a risk factor for NTD. Given the established
protective effects however, of folic acid supplementa-
tion on the occurrence and reoccurrence of NTD, poly-
morphisms in genes encoding the proteins that are
directly involved in folate metabolism, uptake and
transport have been investigated. The reduced activity
of the MTHFR enzyme in individuals with the
MTHFR 677TT genotype, decreases the availability of
5-methyltetrahydrofolate which plays a key role in
methylation(10) and decreases global DNA methyl-
ation(63,64); therefore, it is no surprise that this speciﬁc
mutant gene has been extensively investigated as a gen-
etic risk factor for NTD(65,66).
Over the past two decades, several reports have shown
a 2 to 4-fold increased risk of NTD if the infant or the
mother has the MTHFR 677TT genotype(65,67–70). van
der Put et al.(71) reported an even higher risk of an
NTD pregnancy if both the mother and the fetus were
homozygous for the MTHFR 677CT polymorphism.
The large meta-analysis conducted by Botto and
Yang(9) considered the frequency of the MTHFR
677CT polymorphism and the risk of NTD across a
number of different countries and ethnic groups.
Overall, a 1·8 to 2-fold increased risk of spina biﬁda
was established regardless of whether the infant or the
mother was homozygous for the MTHFR 677CT
polymorphism(9). However, other reports have indicated
that the presence of the MTHFR 677TT genotype in the
infant, and not in the mother, was the relevant consider-
ation in NTD risk(72). Although Shaw et al.(73) estab-
lished an association between the TT genotype and
spina biﬁda risk, only a weak interaction between the
infant genotype and maternal folic acid usage in the
occurrence of spina biﬁda was reported, possibly
suggesting that other contributing factors may also
need to be considered. Studies focusing on maternal
rather than infant MTHFR genotype have found that
maternal folate status and/or maternal homozygosity
for theMTHFR 677CT genotype are important deter-
minants of NTD risk(74,75). Evidence from the aforemen-
tioned meta-analysis suggested that the excess NTD
risk associated with the TT genotype may depend on
folate status and/or a variant of other folate-related
genes(9). Christensen et al.(76) demonstrated a 13-fold
increased risk for spina biﬁda where the TT genotype
was combined with RCF concentrations within the
lowest quartile, a ﬁnding that strongly supports a gene–
nutrient interactive effect being implicated in NTD
risk, and also may explain some of the inconsistencies
within the literature in this area.
Limited studies have investigated the inﬂuence of the
MTHFR TT genotype in relation to present folic acid
recommendations for the prevention of NTD. Prelimi-
nary evidence from a study conducted by our group
reported that among women with the TT genotype,
sampled at the fourteenth gestational week, signiﬁcantly
increased homocysteine and lower RCF concentrations
were observed if folic acid supplementation (400μg/d)
was commenced prior to conception (i.e as rec-
ommended) compared with post-conception (i.e. more
typical practice); such differences were not evident in
the other genotype groups(77). Furthermore, a large ran-
domised controlled trial reported that despite 6 months
supplementation with 4000μg/d folic acid, women of
childbearing age with the TT genotype achieved lower
serum folate concentrations than did those with the CC
genotype(78). Such evidence strongly suggests that folate
requirements are higher in women with the MTHFR
TT genotype and highlights the much greater need for
women with this genotype to adhere to the speciﬁc rec-
ommendation of commencing folic acid prior to con-
ception in order to optimise folate status for the
prevention of NTD, although these ﬁndings need to be
conﬁrmed in larger studies among different populations.
Role of the MTHFR genotype in determining the
risk of hypertensive disorders of pregnancy
Hypertensive disorders of pregnancy, such as
gestational hypertension and preeclampsia affect 5–7%
of all low-risk pregnancies worldwide and are the





















leading cause of maternal and fetal morbidity and
mortality(79). Gestational hypertension occurs without
proteinuria (a predominant feature of preeclampsia),
but increases the risk of developing preeclampsia by
15–26%(80). Historical investigations reported an associ-
ation between gestational hypertension and folate
deﬁciency(81–84).
In the past two decades, a plethora of studies has
investigated the effect of B-vitamin supplementation
on hypertensive disorders of pregnancy. The evidence,
however, remains inconsistent. Bodnar et al.(6) and
Hernandez et al.(7) reported that regular users of a multi-
vitamin containing folic acid compared with non-users,
had a reduced risk of developing preeclampsia and gesta-
tional hypertension by 45 and 55%, respectively.
However, Ray and Mamdani(85) compared the rate of
preeclampsia before and after population-wide fortiﬁca-
tion of food with folic acid in Canada and reported
only a small reduction in the rate of preeclampsia (OR
0·96 (95% CI 0·94, 0·98)). It is possible that such incon-
sistencies may be explained to some extent by different
frequencies of the MTHFR 677CT genotype among
study populations.
Hernandez-Diaz et al.(86) found a signiﬁcant associ-
ation between the MTHFR 677TT genotype and risk
of gestational hypertension and noted that this associ-
ation may be weakened among women taking folic
acid supplementation. Convincing evidence from meta-
analyses has also reported a link between this poly-
morphism and the risk of hypertensive disorders of
pregnancy. Qian et al.(38) conducted a meta-analysis
among Caucasian and Asian populations and reported
a 1·66-fold increased risk of hypertension-in-pregnancy
in T allele carriers; however, signiﬁcant heterogeneity
was noted. Subgroup analysis found that the T allele
was associated with an increased risk of hypertension
in Asians only, whereas no signiﬁcant association was
found in Caucasians. In general agreement with these
ﬁndings, a subsequent meta-analysis that included studies
in Chinese populations only, reported a signiﬁcant
association between the MTHFR 677CT polymorph-
ism and risk of hypertension-in-pregnancy(8).
Apart from gestational hypertension, the closely
related hypertensive-disorder of pregnancy, preeclamp-
sia, has separately been investigated in relation to the
MTHFR 677CT polymorphism. In 1997, two separate
case–control studies independently reported a signiﬁcant
association between the TT genotype and preeclamp-
sia(87,88). Since then, numerous studies have investigated
this association; however, conﬂicting results have
emerged (Table 2). Worldwide, Mexico has the highest
frequency of the TT genotype(89) as well as a high preva-
lence of preeclampsia(90). Within populations from two
regions of Mexico, however, Perez-Mutul et al.(91) and
Davalos et al.(92) reported no signiﬁcant association
between the polymorphism and preeclampsia in pregnant
women. In contrast, Canto et al.(93) reported from
another group of pregnant Mexican women, that the
TT genotype (compared to the CC and CT genotypes)
was associated with a decreased risk of preeclampsia, fol-
lowing adjustment for age and BMI. Such discrepancies
between studies may suggest that the effect of the
MTHFR 677TT genotype may be modulated by relevant
dietary and environmental factors that could vary con-
siderably among different populations.
The association between the MTHFR 677CT poly-
morphism and preeclampsia has been addressed in sev-
eral meta-analyses. Kosmas et al.(94) reported that the
TT genotype compared with the CC genotype was as-
sociated with a 33% increased risk of preeclampsia, how-
ever signiﬁcant between-study heterogeneity was found.
Most recently, the meta-analysis by Xia et al.(95) reported
that the TT genotype compared with the CC and CT
genotypes carried a signiﬁcantly greater risk of pree-
clampsia (by 76%) among Asian women only, whereas
in Caucasian women this increased risk was not evident.
It is worth noting however that a much greater number of
large-scale studies in this area have been conducted
within Asian populations with far fewer studies con-
ducted in Caucasian populations; a factor that limits
Table 2. Studies that investigated the association between the MTHFR 677CT polymorphism and preeclampsia risk
Author Sample size Country/population Odds ratio (95% CI)
Sohda et al.(87) 425 Japan 2·5 (1·3, 4·8)
Grandone et al.(88) 225 Italy 1·8 (1·0, 3·5)
Kupferminc(96) 144 Israel 2·9 (1·0, 8·5)
Powers et al.(97) 237 Caucasian women 1·28 (0·58, 2·79)
Kobashi et al.(98) 316 Japan 0·68 (0·30, 1·55)
Laivuori et al.(99) 216 Finland 0·50 (0·14, 1·77)
Rigo et al.(100) 221 Caucasian women 1·13 (0·38, 3·37)
Morrison et al.(101) 404 Scotland 1·00 (0·55, 1·82)
Prasmusinto et al.(102) 112 Germany and Croatia 0·28 (0·03, 2·47)
Pegoraro et al.(103) 609 South African (Black) 0·62 (0·06, 6·90)
Perez-Mutul et al.(91) 325 Mexico 0·94 (0·59, 1·49)
Williams et al.(104) 304 Peru 1·6 (0·7, 3·8)
Yilmaz et al.(105) 111 Turkey 0·84 (0·26, 2·67)
Also-Rallo et al.(79) 165 Spain 0·73 (0·31, 1·76)
Hernandez-Diaz et al.(86) 154 USA/Canada 3·0 (1·2, 7·7)
Stiefel et al.(106) 584 Spain 0·92 (0·50, 1·71)





















the extent to which different populations can be com-
pared. An additional limitation is that genotype-driven
recruitment is generally not undertaken in these studies,
a feature that is reﬂected by the relatively small numbers
of pregnant women with the TT genotype being investi-
gated and these raised the concern that many such studies
may be statistically underpowered. It is not surprising
therefore that in some cases the association between the
MTHFR polymorphism and gestational hypertension is
found to be relatively weak. In addition, the modulating
effects of the polymorphism in relation to hypertension
may be masked by the presence of other risk factors,
such as reduced physical activity, increased BMI and
gestational diabetes, which can develop during preg-
nancy and increase BP.
Conclusion
Overall, convincing evidence supports an independent
role for the MTHFR 677CT polymorphism as a risk
factor for a number of adverse health outcomes, but
there are considerable inconsistencies among individual
studies. The MTHFR 677TT genotype has been shown
in several populations to be an important determinant
of hypertension and this may provide a possible expla-
nation for the excess risk of CVD generally linked
with this polymorphism as reported in numerous
meta-analyses. In addition to the widely acknowledged
modulating role of folate, riboﬂavin (which has been lar-
gely overlooked to date) is emerging as an important
nutrient that drives the phenotype and potentially the
disease risk associated with the MTHFR 677CT poly-
morphism. Given the genotype-speciﬁc responsiveness of
BP to riboﬂavin intervention demonstrated in trials from
this Centre, it is possible that the large geographical vari-
ations in the extent of disease risk may relate not only to
comprised folate status, as commonly suggested, but may
also be the result of differences in prevailing riboﬂavin
status among different populations. Large genotype-
driven intervention trials (involving pre-screening to
select individuals with the TT genotype) conducted
within unfortiﬁed regions or among populations with
sub-optimal B-vitamin status are required to conﬁrm
this. Overall, there is convincing evidence of the potential
for a personalised approach to disease prevention or
treatment, whereby B-vitamin intervention may be tar-
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